Methods for treating cells containing fusion genes

A method of treating a subject having prostate cancer, comprising determining whether a sample of the subject contains one or more fusion genes selected from the group consisting of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1, CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1, PCMTD1-SNTG1 and a combination thereof;

• and where if one or more fusion genes are detected in the sample then performing a CRISPR/Cas genome editing technique targeting the one or more fusion genes present within one or more prostate cancer cells of the subject,
• wherein the genome editing technique comprises introducing into the one or more prostate cancer cells:
• (i) a vector comprising a nucleic acid encoding a Cas protein or a mutant thereof and two guide RNAs (gRNA), wherein one gRNA is complementary to a region within one gene of the fusion gene and a second gRNA is complementary to a region within a second gene of the fusion gene, and (ii) a vector comprising a donor nucleic acid and one or more targeting sequences,
• wherein the two gRNAs direct binding of the Cas 9 protein or mutant thereof to a genomic sequence of the fusion gene to promote cleavage of the fusion gene and insertion of the donor nucleic acid into the fusion gene, and wherein expression of the donor nucleic acid induces cell death of the one or more prostate cancer cells.